Consensus is for FY25 revenue 5.03B. Raises FY25 Full-Year Adjusted EBITDA Excluding Acquired IPR&D view to $860M-$910M from $850M-$900M.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BLCO:
- Bausch + Lomb Confirms Efficacy of LUMIFY Preservative Free Eye Drops
- Bausch + Lomb publishes Lumify eye drops data in Ophthalmology and Therapy
- Bausch + Lomb Amends CEO Employment Agreement
- Bausch + Lomb price target raised to $15 from $13 at Citi
- Mixed Product Performance and Market Challenges Justify Hold Rating for Bausch + Lomb